| [1] |
Walsh A, Mabee J, Trivedi K. Inflammatory bowel disease [J]. Prim Care, 2011, 38 (3):415-432.
|
| [2] |
Vindigni SM, Zisman TL, Suskind DL.et al. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions [J]. Therap Adv Gastroenterol, 2016, 9(4):606-625.
|
| [3] |
罗涵青, 钱家鸣.沙利度胺在顽固性炎症性肠病中的应用 [J]. 中华内科杂志, 2012, 51(11):905-906.
|
| [4] |
Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies ininflammatory bowel disease: systematic review and meta-analysis [J]. Am J Gastroenterol, 2011, 106(4): 644-659.
|
| [5] |
Wettstein AR, Meagher AP.Thalidomide in Crohn′s disease [J]. Lancet, 1997, 350(9088):1445-1446.
|
| [6] |
Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn′s disease [J]. Gastroenterology, 1999, 117(6):1278-1287.
|
| [7] |
Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn′s disease: an open-label trial [J]. Gastroenterology, 1999, 117(6):1271-1277.
|
| [8] |
Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumor necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn′s disease [J]. Gut, 2002, 50(2):196-200.
|
| [9] |
Gerich ME, Yoon1 GL, Targan SR, et al. Long-term outcomes of thalidomide in refractory Crohn′s disease [J]. Aliment Pharmacol Ther, 2015, 41(5): 429-437.
|
| [10] |
Simon M, Pariente B, Lambert J, et al. Long-term Outcomes of Thalidomide Therapy for Adults with Refractory Crohn′s Disease [J]. Clinl Gastroenterol Hepatol, 2015, 14(7):966-972.
|
| [11] |
Diamanti A, Capriati T, Papadatou B, et al. The clinical implications of thalidomide in inflammatory bowel diseases [J]. Expert Rev Clin Immunol, 2015, 11(6):699-708.
|
| [12] |
Facchini S, Candusso M, Martelossi S, et al. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results [J]. J Ped Gastroenterol Nutr, 2001, 32(2):178-181.
|
| [13] |
Lazzerini M, Martelossi S, Marchetti F, et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results [J]. Aliment Pharmacol Ther, 2007, 25(4): 419-427.
|
| [14] |
Lazzerini M, Marteloss i S, Magazzu G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial [J]. JAMA, 2013, 310(20):2164-2173.
|
| [15] |
Lazzerini M, Martelossi S, Cont G, et al. Orofacial granulomatosis in children: Think about Crohn′s disease [J]. Dig Liver Dis, 2015, 47(4); 338–341.
|
| [16] |
Waters MFR, Laing ABG, Ambikapathy A, et al. Treatment of ulcerative colitis with thalidomide [J]. Br Med J, 1979, 1(6166):792.
|
| [17] |
Lazzerini M, Martelossi S, Magazzu G, et al. Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial [J]. Inflamm Bowel Dis, 2015, 21(8):1739-1749.
|
| [18] |
Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes [J]. J Exp Med, 1991, 173(3):699–703.
|
| [19] |
Felipez LM, Gokhale R, Tierney MP, et al. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab [J]. J Pediatr Gastroenterol Nutr, 2012, 54(1):28-33.
|
| [20] |
Rafiee P, Stein DJ, Nelson VM, et al. Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelialcells (HIMEC) [J]. Am J Physiol Gastrointest Liver Physiol, 2010, 298(2):G167–176.
|
| [21] |
Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NF-Kb activity by thalidomide through suppression of IkB kinase activity [J]. J Biol Chem, 2001, 276(25): 22382–22387.
|
| [22] |
Laffitte E, Revuz J. Thalidomide: an old drug with new clinical applications [J]. Expert Opin Drug Saf, 2004, 3(1):47-56.
|
| [23] |
Cavalletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study [J]. Neurology, 2004, 62(12):2291-2293.
|
| [24] |
Ruemmele FM, Veres G, Kolho KL, et al.Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn′s disease [J]. J Crohns Colitis, 2014, 8(10):1179-1207.
|